Report-store Details

  • Home
  • Report-store Details
Contact Us
+1 (732) 526 1166
India: 040-46013143

Email Us

Report Type : Therapy Reports
Report Category : Cardiovascular
Report Subcategory : Atrial Fibrillation
Price : 2999.00
Date : July 2021
Atrial Fibrillation : Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Atrial Fibrillation
Atrial fibrillation is an irregular and often rapid heart rate that can increase your risk of strokes, heart failure and other heart-related complications.

During atrial fibrillation, the heart's two upper chambers (the atria) beat chaotically and irregularly — out of coordination with the two lower chambers (the ventricles) of the heart. Atrial fibrillation symptoms often include heart palpitations, shortness of breath and weakness.

Episodes of atrial fibrillation may come and go, or you may develop atrial fibrillation that doesn't go away and may require treatment. Although atrial fibrillation itself usually isn't life-threatening, it is a serious medical condition that sometimes requires emergency treatment.

A major concern with atrial fibrillation is the potential to develop blood clots within the upper chambers of the heart. These blood clots forming in the heart may circulate to other organs and lead to blocked blood flow (ischemia).

Top & Promising Drugs by Company:
Sanofi- Plavix (clopidogrel bisulfate)
Daiichi Sankyo Co Ltd- Roteas (edoxaban tosylate)
AstraZeneca Plc- Betaloc Zok (metoprolol succinate ER)
Daiichi Sankyo Co Ltd- Artist (carvedilol)
Waymade Plc- Tenormin (Tenormin)
Pfizer Inc- Chronovera (verapamil hydrochloride ER)
Sanofi- Multaq (dronedarone hydrochloride)
Bristol-Myers Squibb Co- Coumadin (warfarin sodium)
Pfizer Inc- Tikosyn (dofetilide)
Mitsubishi Chemical Holdings Corp- Maintate (bisoprolol fumarate)

Have a business Query? Let's Talk.

Email : or Call : +1 (732) 526 1166
India: 040-46013143

Get The Latest Updates

Signup For Newsletter

(c) 2021 Sciinov Group - All rights reserved.